ArticleCancer medicine2024

Preclinical evidence for the use of anti-Trop-2 antibody-drug conjugate Sacituzumab govitecan in cerebral metastasized castration-resistant prostate cancer.

Richard Weiten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.